Global Oncology | Specialty

The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.

TUB-040 Represents Novel ADC Approach in Platinum-Resistant Ovarian Cancer

December 3rd 2025

Antonio González-Martín, MD, PhD, discusses data for TUB-040 in platinum-resistant ovarian cancer and how it stacks up against other ADCs.

Subcutaneous Pembrolizumab Approved in EU for All Adult Indications

December 1st 2025

Pembrolizumab obtained approval from the European Commission for subcutaneous administration for all adult indications.

NICE Recommends Obe-Cel for Adult R/R B-ALL

December 1st 2025

NICE has recommended obecabtegene autoleucel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

European Commission Approves Liso-Cel for R/R Mantle Cell Lymphoma

November 25th 2025

Liso-cel was approved in the EU for relapsed/refractory MCL after at least 2 lines of therapy, including a BTK inhibitor.

Sacituzumab Tirumotecan Plus Pembrolizumab Improves PFS in PD-L1+ Advanced NSCLC

November 24th 2025

Sacituzumab tirumotecan plus pembrolizumab improved PFS as first-line treatment in PD-L1–positive advanced NSCLC.

European Commission Approves Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma

November 19th 2025

The European Commission has approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma.

Adjuvant Cemiplimab Cleared in EU for CSCC With High Recurrence Risk After Surgery and Radiation

November 19th 2025

Cemiplimab wins EU approval after C-POST shows DFS gains for high-risk CSCC, marking the first effective adjuvant immunotherapy option.

PanTRKare Approved in China as Companion Diagnostic for Entrectinib in NTRK+ Solid Tumors

November 17th 2025

PanTRKare was approved in China as a companion diagnostic to identify patients with NTRK fusion–positive solid tumors who may be eligible for entrectinib.

Sequential CAR T-Cell Therapy and ASCT Yields Durable Remissions in Ph-Negative B-ALL

November 12th 2025

Phase 2 data showed high 2-year survival and deep MRD-negative remissions with a CD22/CD19 CAR T-cell therapy and ASCT “sandwich” approach in B-ALL.

China’s Center for Drug Evaluation Grants Breakthrough Therapy Designation to Ivonescimab in TNBC

November 4th 2025

Ivonescimab plus chemotherapy has received breakthrough therapy designation as first-line therapy in patients with triple-negative breast cancer.

OncLive’s October EMA Regulatory Recap: Key EU Approvals in Oncology

November 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in October 2025.

Cemiplimab Receives Reimbursement in Seven Provinces for NSCLC, Basal Cell Carcinoma

October 31st 2025

Seven provinces have agreed to reimburse cemiplimab for the treatment of patients with advanced non–small cell lung cancer and basal cell carcinoma.

Mirvetuximab Soravtansine Receives Positive Reimbursement Recommendation From Canada’s Drug Agency for Platinum-Resistant Ovarian Cancer

October 31st 2025

Mirvetuximab soravtansine has received a positive reimbursement recommendation in Canada under the Target Zero initiative for platinum-resistant ovarian cancer.

Pembrolizumab-Based Combo Wins EU Approval for PD-L1+ Resectable Locally Advanced HNSCC

October 29th 2025

The European Commission approved perioperative pembrolizumab plus adjuvant radiotherapy with or without cisplatin in resectable locally advanced HNSCC.

Selumetinib Nets EU Approval for Adult NF1-Associated Plexiform Neurofibromas

October 28th 2025

Selumetinib has received approval in the EU for the management of plexiform neurofibromas in adult patients with neurofibromatosis type 1.

Toripalimab Becomes First Approved Immunotherapy for Recurrent Unresectable/Metastatic NPC in Canada

October 24th 2025

Toripalimab has been approved by Health Canada both as monotherapy and in combination with cisplatin and gemcitabine for recurrent or metastatic NPC.

Asciminib Receives Positive CHMP Opinion for Ph+ CP-CML

October 17th 2025

The EMA’s CHMP has recommended the approval of asciminib for Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Adjuvant Cemiplimab Recommended for European Approval in CSCC

October 17th 2025

The EMA’s CHMP has recommended the approval of adjuvant cemiplimab in CSCC at high risk of recurrence after surgery and radiation

Izalontamab Brengitecan Data Reinforce the Value of ADCs in Advanced Urothelial Carcinoma

October 15th 2025

Izalontamab brengitecan showed signals of activity in patients with pretreated locally advanced or metastatic urothelial carcinoma.

EU Approval Sought for Relacorilant in Platinum-Resistant Ovarian Cancer

October 14th 2025

The approval of relacorilant for use in patients with platinum-resistant ovarian cancer is sought from the European Medicines Agency.